Phase 3 N=426 LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Treatment Success According to IGA — 53.3; 4.8 percentage of subjects — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=107 Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Cystic Fibrosis
Primary: Rate of Protocol-defined Exacerbations (PDE) From Baseline Through Week 24 — 1.309; 1.762 PDEs per participant year — p=0.25
Phase 3 N=63 A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Hemophilia B
Primary: Change in Frequency of Spontaneous Bleeding Events Between On-demand and Prophylaxis Treatments (Annualized) — 15.43; 0.00 bleeds/year/subject — p=<0.0001
Phase 3 N=450 Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AKs 8 Weeks After Randomisation — 43; 9; 25; 5 participants — p=0.001
Phase 3 N=161 Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
Open Angle Glaucoma · Ocular Hypertension
Primary: Number of Subjects With AEs — 140 participants
Phase 3 N=94 Treximet Early Intervention Adolescent Migraine
Migraine
Primary: Number of Participants With 2-hour Pain Free Active Study Drug — 35; 23; 21; 24 Participants — p=0.0038
Phase 3 N=269 Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: PFS (Progression Free Survival) — NA; 18.9 Months — p=<0.0001
Phase 3 N=298 Treatment Options for Protease Inhibitor-exposed Children
HIV/AIDS · HIV Infections
Primary: Viral Rebound — 0.284; 0.176 probability of viral rebound — p=<0.001
Phase 3 N=1,561 Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer
Lung Cancer
Primary: Incidence Rate of Second Primary Lung Tumor — 1.30; 1.62 cases/100 person years — p=0.294
Phase 3 N=1,429 Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
Schizophrenia
Primary: Percentage of Participants Without Relapse at Week 48 During the Double-Blind Phase — 91.5; 90.0 Percentage of Participants
Phase 3 N=2,808 A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
Bacterial Infections · Virus Diseases
Primary: Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen — 5.51; 6.10; 6.59; 3.76 µg/mL — p=<0.001
Phase 3 N=463 LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Treatment Success According to the PGA — 38.3; 22.5 percentage of subjects — p=<0.001
Phase 3 N=163 LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Anemia
Primary: Percentage of Participants Maintaining Their Mean Hb Concentration Within ±1.0 Gram/Deciliter of Their Reference Hb and Between 10.5 and 12.5 Gram/Deciliter — 43.7…
Phase 3 N=485 Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis
Bronchiectasis
Primary: Rate of Graded Pulmonary Exacerbations — 1.95; 2.10; 1.69; 1.84 GPE events per year — p=0.3115
Phase 3 N=821 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Primary: Overall Survival (OS) at Primary Endpoint — 25.00; 19.55 months — p=0.0018